Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237

Neuro-Oncology

Volumn 5, Issue 4, 2003, Pages 261-267

  Dreyer, ZoAnn E ^a   Kadota, Richard P ^b   Stewart, Clinton F ^c   Friedman, Henry S ^d   Mahoney, Donald H ^a   Kun, Larry E ^c   McCluggage, Charles W ^e   Burger, Peter C ^f   Kepner, James ^g   Heideman, Richard L ^h  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e ST LUKE S EPISCOPAL HOSPITAL   (United States)

^f JOHNS HOPKINS HOSPITAL   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IDARUBICINOL;

ADOLESCENT; ADULT; ARTICLE; ASTROCYTOMA; BLEEDING; BLOOD CELL COUNT; BLOOD TOXICITY; BRAIN STEM TUMOR; BRAIN TUMOR; CANCER GROWTH; CARDIOTOXICITY; CHICKENPOX; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG RESPONSE; EPENDYMOMA; FEMALE; GLIOBLASTOMA; GLIOMA; GRAM NEGATIVE SEPSIS; HUMAN; INFANT; INFECTION; KIDNEY DYSFUNCTION; LEUKEMIA; LUNG ABSCESS; MALE; MEDULLOBLASTOMA; NEUTROPENIA; PARTITION COEFFICIENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PYREXIA IDIOPATHICA; SEIZURE; STOMATITIS; TEMPORAL LOBE; THROMBOCYTOPENIA; TUMOR RECURRENCE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IDARUBICIN; INFANT; MALE;

EID: 0142029077     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/S115285170200056X     Document Type: Article

References (13)

1. Arndt, C.A., Krailo, M.D., Steinherz, L., Scheithauer, B., Liu-Mares, W., and Reaman, G.H. (1998) A phase II clinical trial of idarubicin administered to children with relapsed brain tumors. Cancer 83, 813-816.
2. Berg, S.L., Reid, J., Godwin, K., Murry, D.J., Poplack, D.G., Balis, F.M., and Ames, M.M. (1999) Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. J. Pediatr. Hematol. Oncol. 21, 26-30.
3. Bushunow, P., Mechtler, L., Mogensen, K., Winfield, J., Lemke, S., and Coyle, T. (1998) Idarubicin for treatment of recurrent malignant glial tumors: A Buffalo-Rochester-Syracuse Neuro-oncology Study Group trial. Proc. Am. Soc. Clin. Oncol. 17, 386a (abstract).
4. Daghestani, A., Arlin, Z.A., Leyland-Jones, B., Gee, T.S., Kempin, S.J., Mertelsmann, R., Budman, D., Schulman, P., Baratz, R., Williams, L., Clarkson, B., and Young, C. (1985) Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. Cancer Res. 45, 1408-1412.
5. de Graff, S.S., Riley-Stewart, C.A., and Evans, W.E. (1989) Improved high-performance liquid chromatographic method using loop-column extraction for analysis of idarubicin and idarubicinol in plasma. J. Chromatogr. A 491, 501-506.
6. Gehan, E.A. (1961) The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J. Chronic Dis. 13, 346-353.
7. Izumoto, S., Arita, N., Hayakawa, T., Ohnishi, T., Taki, T., Yamamoto, H., and Ushio, Y. (1990) Effect of MX2, a new morpholino anthracycline, against experimental brain tumors. Anticancer Res. 10, 735-739.
8. Kuffel, M.J., Reid, J.M., and Ames, M.M. (1992) Anthracyclines and their C-13 alcohol metabolites: Growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother. Pharmacol. 30, 51-57.
9. NCI, National Cancer Institute. (1993) Investigators Handbook. A Manual for Participants in Clinical Trials of Investigational Agents Sponsored by the Division of Cancer Treatment, National Cancer Institute. Washington, D.C.: Department of Health and Human Services, 153-157.
10. Reid, J.M., Pendergrass, T.W., Krailo, M.D., Hammond, G.D., and Ames, M.M. (1990) Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: A Children's Cancer Study Group report. Cancer Res. 50, 6525-6528.
11. Schott, B., and Robert, J. (1989) Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells. Biochem. Pharmacol. 38, 169-172.
12. Speth, P.A., Minderman, H., and Haanen, C. (1989) Idarubicin v daunorubicin: Preclinical and clinical pharmacokinetic studies. Semin. Oncol. 16, 2-9.
13. Tan, C.T., Hancock, C., Steinherz, P., Bacha, D.M., Steinherz, L., Luks, E., Winick, N., Meyers, P., Mondora, A., Dantis, E., Niedzwiecki, D., and Stevens, Y. (1987) Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. Cancer Res. 47, 2990-2995.